MX2019000048A - Una cepa de virus atenuada de peste porcina africana desarrollada racionalmente que protege contra el desafio con el virus parental georgia 2007 aislado. - Google Patents
Una cepa de virus atenuada de peste porcina africana desarrollada racionalmente que protege contra el desafio con el virus parental georgia 2007 aislado.Info
- Publication number
- MX2019000048A MX2019000048A MX2019000048A MX2019000048A MX2019000048A MX 2019000048 A MX2019000048 A MX 2019000048A MX 2019000048 A MX2019000048 A MX 2019000048A MX 2019000048 A MX2019000048 A MX 2019000048A MX 2019000048 A MX2019000048 A MX 2019000048A
- Authority
- MX
- Mexico
- Prior art keywords
- asfv
- georgia
- swine fever
- african swine
- isolate
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title abstract 4
- 208000007407 African swine fever Diseases 0.000 title abstract 3
- 230000002238 attenuated effect Effects 0.000 title abstract 2
- 241000701386 African swine fever virus Species 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 229960005486 vaccine Drugs 0.000 abstract 3
- 241001465754 Metazoa Species 0.000 abstract 1
- 241000282887 Suidae Species 0.000 abstract 1
- 241000282898 Sus scrofa Species 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 231100000518 lethal Toxicity 0.000 abstract 1
- 230000001665 lethal effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- 230000001018 virulence Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12061—Methods of inactivation or attenuation
- C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/12011—Asfarviridae
- C12N2710/12071—Demonstrated in vivo effect
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/18—Togaviridae; Flaviviridae
- G01N2333/183—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus) or border disease virus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
Abstract
El virus de la peste porcina africana (VPPA, por sus ?siglas en inglés) es el agente etiológico de una enfermedad viral contagiosa, a menudo letal, de los cerdos domésticos. El control de la peste porcina africana (ASF) se ha visto obstaculizado por la falta de disponibilidad de vacunas. Las vacunas experimentales se han derivado de VPPA atenuados vivos, adaptados a cultivos de células o modificados genéticamente; sin embargo, estas vacunas solo tienen éxito cuando protegen contra virus homólogos. Hemos construido un virus recombinante ?9GL/?UK derivado del virus VPPA Georgia 2007 (VPPA-G) altamente virulento al eliminar los genes específicos asociados a la virulencia 9GL(B119L) y el UK(DP96R). In vivo, VPPA-G ?9GL/?UK administrado por vía intramuscular a los cerdos, incluso a dosis relativamente altas (106HAD50) no induce enfermedad. Es importante destacar que los animales infectados con 104 o 106 HAD50 están sólidamente protegidos contra la presentación de la enfermedad clínica cuando se los desafía a los 28 días posteriores a la infección con la cepa parental virulenta Georgia 2007.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15/200,407 US9808520B1 (en) | 2016-07-01 | 2016-07-01 | Rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate |
| PCT/US2017/039277 WO2018005358A1 (en) | 2016-07-01 | 2017-06-26 | A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019000048A true MX2019000048A (es) | 2019-07-04 |
Family
ID=60189680
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019000048A MX2019000048A (es) | 2016-07-01 | 2017-06-26 | Una cepa de virus atenuada de peste porcina africana desarrollada racionalmente que protege contra el desafio con el virus parental georgia 2007 aislado. |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9808520B1 (es) |
| EP (1) | EP3478705B1 (es) |
| JP (1) | JP7121950B2 (es) |
| KR (1) | KR102443074B1 (es) |
| CN (1) | CN109952310B (es) |
| AU (1) | AU2017288932B2 (es) |
| BR (1) | BR112018076633A2 (es) |
| CA (1) | CA3029552A1 (es) |
| CL (1) | CL2018003769A1 (es) |
| DK (1) | DK3478705T3 (es) |
| EA (1) | EA201990085A1 (es) |
| ES (1) | ES2971606T3 (es) |
| FI (1) | FI3478705T3 (es) |
| GE (1) | GEP20207186B (es) |
| HR (1) | HRP20240254T1 (es) |
| HU (1) | HUE065240T2 (es) |
| LT (1) | LT3478705T (es) |
| MX (1) | MX2019000048A (es) |
| MY (1) | MY197376A (es) |
| PH (1) | PH12018502684A1 (es) |
| PL (1) | PL3478705T3 (es) |
| PT (1) | PT3478705T (es) |
| RS (1) | RS65124B1 (es) |
| SG (1) | SG11201811370XA (es) |
| SI (1) | SI3478705T1 (es) |
| UA (1) | UA125584C2 (es) |
| WO (1) | WO2018005358A1 (es) |
| ZA (1) | ZA201900259B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017128039A1 (zh) * | 2016-01-26 | 2017-08-03 | 浙江大学 | 基因组合及其用途 |
| CN110302371B (zh) * | 2019-08-21 | 2023-05-26 | 军事科学院军事医学研究院军事兽医研究所 | 灭活asfv作为复合疫苗的免疫攻毒保护成分的用途 |
| US11007263B2 (en) | 2019-09-24 | 2021-05-18 | The United States Of America, As Represented By The Secretary Of Agriculture | Development of a novel live attenuated African Swine Fever vaccine based in the deletion of gene I177L |
| JP7382628B2 (ja) * | 2019-10-11 | 2023-11-17 | 国立研究開発法人農業・食品産業技術総合研究機構 | アフリカ豚コレラウイルスの製造方法及び検出方法 |
| CN110760617B (zh) * | 2019-11-26 | 2021-12-21 | 华中农业大学 | 检测非洲猪瘟病毒野毒的实时荧光pcr引物探针组合及试剂盒 |
| KR20210087810A (ko) | 2020-01-03 | 2021-07-13 | 주식회사 중앙백신연구소 | 신규한 아프리카돼지열병의 예방 및 치료를 위한 바이러스 백신조성물 |
| CN111925994B (zh) * | 2020-07-03 | 2023-05-26 | 中国农业科学院兰州兽医研究所 | 一种dp71l基因缺失的重组非洲猪瘟病毒及其制备方法和应用 |
| CN111748563A (zh) * | 2020-07-10 | 2020-10-09 | 中国农业科学院兰州兽医研究所 | 非洲猪瘟基因缺失弱毒株的构建及其作为疫苗的应用 |
| CN112063592A (zh) * | 2020-07-10 | 2020-12-11 | 中国农业科学院兰州兽医研究所 | 非洲猪瘟多基因联合缺失减毒株的构建及作为疫苗的应用 |
| CN111996175B (zh) * | 2020-09-04 | 2023-11-21 | 军事科学院军事医学研究院军事兽医研究所 | 缺失e66l、i267l基因的非洲猪瘟减毒及活疫苗 |
| WO2022107793A1 (ja) * | 2020-11-20 | 2022-05-27 | 国立研究開発法人農業・食品産業技術総合研究機構 | 不死化豚胎子小腸マクロファージ |
| CN117043177A (zh) | 2020-12-24 | 2023-11-10 | 英特维特国际股份有限公司 | 非洲猪瘟diva免疫测定 |
| CN112852761B (zh) * | 2021-03-08 | 2022-08-23 | 中国农业科学院兰州兽医研究所 | 基因缺失减毒非洲猪瘟病毒株的构建及作为疫苗的应用 |
| CN114392345B (zh) * | 2021-03-11 | 2023-08-25 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | E199l蛋白在促进细胞凋亡中的用途及方法 |
| CN113061588B (zh) * | 2021-05-20 | 2023-08-01 | 军事科学院军事医学研究院军事兽医研究所 | 缺失i226r基因的非洲猪瘟病毒减毒株及其活疫苗 |
| US11801296B2 (en) | 2021-06-30 | 2023-10-31 | The United States Of America, As Represented By The Secretary Of Agriculture | Development of a novel live attenuated African swine fever vaccine based in the deletion of gene A137R |
| CN114107228B (zh) * | 2021-11-11 | 2023-06-13 | 中国农业科学院兰州兽医研究所 | 缺失十二个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用 |
| CN113831394B (zh) * | 2021-11-29 | 2022-04-12 | 中国人民解放军军事科学院军事医学研究院 | 一种非洲猪瘟病毒asfv基因的重组病毒组合及由其制备的疫苗 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8610106D0 (en) * | 1986-04-25 | 1986-05-29 | Central Blood Lab Authority | Human igm-producing heterohybridoma |
| US8846055B2 (en) * | 2006-05-30 | 2014-09-30 | The United States Of America, As Represented By The Secretary Of Agriculture | Virulence determinant within the E2 structural glycoprotein of classical swine fever virus |
| US9352032B2 (en) * | 2014-03-07 | 2016-05-31 | The United States Of America As Represented By The Secretary Of Agriculture | Live attenuated antigenically marked classical swine fever vaccine |
| GB201410971D0 (en) * | 2014-06-19 | 2014-08-06 | Pirbright Inst The | Vaccine |
| US9463234B2 (en) * | 2014-09-24 | 2016-10-11 | The United States Of America, As Represented By The Secretary Of Agriculture | Attenuated african swine fever virus strain induces protection against challenge with homologous virulent parental virus georgia 2007 isolate |
| US9528094B2 (en) * | 2014-11-10 | 2016-12-27 | The United States Of America, As Represented By The Secretary Of Agriculture | Attenuated African swine fever virus vaccine based in the deletion of MGF genes |
-
2016
- 2016-07-01 US US15/200,407 patent/US9808520B1/en active Active
-
2017
- 2017-06-26 JP JP2018568233A patent/JP7121950B2/ja active Active
- 2017-06-26 UA UAA201900970A patent/UA125584C2/uk unknown
- 2017-06-26 CN CN201780053651.9A patent/CN109952310B/zh active Active
- 2017-06-26 BR BR112018076633-0A patent/BR112018076633A2/pt unknown
- 2017-06-26 FI FIEP17821008.4T patent/FI3478705T3/fi active
- 2017-06-26 GE GEAP201714984A patent/GEP20207186B/en unknown
- 2017-06-26 SG SG11201811370XA patent/SG11201811370XA/en unknown
- 2017-06-26 MX MX2019000048A patent/MX2019000048A/es unknown
- 2017-06-26 MY MYPI2018002721A patent/MY197376A/en unknown
- 2017-06-26 EP EP17821008.4A patent/EP3478705B1/en active Active
- 2017-06-26 HU HUE17821008A patent/HUE065240T2/hu unknown
- 2017-06-26 SI SI201731488T patent/SI3478705T1/sl unknown
- 2017-06-26 DK DK17821008.4T patent/DK3478705T3/da active
- 2017-06-26 PL PL17821008.4T patent/PL3478705T3/pl unknown
- 2017-06-26 KR KR1020197003279A patent/KR102443074B1/ko active IP Right Grant
- 2017-06-26 ES ES17821008T patent/ES2971606T3/es active Active
- 2017-06-26 HR HRP20240254TT patent/HRP20240254T1/hr unknown
- 2017-06-26 EA EA201990085A patent/EA201990085A1/ru unknown
- 2017-06-26 WO PCT/US2017/039277 patent/WO2018005358A1/en unknown
- 2017-06-26 AU AU2017288932A patent/AU2017288932B2/en active Active
- 2017-06-26 CA CA3029552A patent/CA3029552A1/en active Pending
- 2017-06-26 LT LTEPPCT/US2017/039277T patent/LT3478705T/lt unknown
- 2017-06-26 RS RS20240124A patent/RS65124B1/sr unknown
- 2017-06-26 PT PT178210084T patent/PT3478705T/pt unknown
-
2018
- 2018-12-19 PH PH12018502684A patent/PH12018502684A1/en unknown
- 2018-12-21 CL CL2018003769A patent/CL2018003769A1/es unknown
-
2019
- 2019-01-15 ZA ZA2019/00259A patent/ZA201900259B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018502684A1 (en) | A rationally developed african swine fever attenuated virus strain protects against challenge with parental virus georgia 2007 isolate | |
| Weger-Lucarelli et al. | A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice | |
| Skinner et al. | Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry | |
| RU2017113571A (ru) | Рекомбинантные вакцины от fmdv и их применение | |
| Stading et al. | Protection of bats (Eptesicus fuscus) against rabies following topical or oronasal exposure to a recombinant raccoon poxvirus vaccine | |
| JP2017530124A5 (es) | ||
| JP2017502662A5 (es) | ||
| Loy et al. | Development and evaluation of a replicon particle vaccine expressing the E2 glycoprotein of bovine viral diarrhea virus (BVDV) in cattle | |
| Yang et al. | Type I Interferons Triggered through the Toll-Like Receptor 3–TRIF Pathway Control Coxsackievirus A16 Infection in Young Mice | |
| Bassi et al. | Vaccination with replication deficient adenovectors encoding YF-17D antigens induces long-lasting protection from severe yellow fever virus infection in mice | |
| Moreno et al. | Recombinant Rift Valley fever viruses encoding bluetongue virus (BTV) antigens: Immunity and efficacy studies upon a BTV-4 challenge | |
| Golden et al. | The strategic use of novel smallpox vaccines in the post-eradication world | |
| EA201790296A1 (ru) | Вакцина в виде рекомбинантного вектора на основе птичьего аденовируса серотипа 9 | |
| Gutiérrez-Álvarez et al. | Middle East respiratory syndrome coronavirus vaccine based on a propagation-defective RNA replicon elicited sterilizing immunity in mice | |
| NI201700080A (es) | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas. | |
| Vasconcelos et al. | Are booster doses of yellow fever vaccine needed? | |
| Jones et al. | Raccoonpoxvirus safety in immunocompromised and pregnant mouse models | |
| RU2017137498A (ru) | Рекомбинантный нокаутный мутант вируса нодулярного дерматита и его применение | |
| Kim et al. | Stability and efficacy of the 3′-UTR A4G-G5A variant of viral hemorrhagic septicemia virus (VHSV) as a live attenuated immersion VHSV vaccine in olive flounder (Paralichthys olivaceus) | |
| Zanetti et al. | Canarypox virus expressing infectious bursal disease VP2 protein as immunogen for chickens | |
| Rocke et al. | Further development of raccoon poxvirus-vectored vaccines against plague (Yersinia pestis) | |
| TN2014000393A1 (en) | Modified marek's disease virus, and vaccines made therefrom | |
| Roper | Poxvirus safety analysis in the pregnant mouse model, vaccinia, and raccoonpox viruses | |
| Braun et al. | Genetic variability of myxoma virus genomes | |
| CN117230027A (zh) | 一种非洲猪瘟病毒减毒毒株、其制备方法及应用 |